Cavitation, low density areas, and stenosis of responsible bronchus are risk factors for infectious complications after endobronchial ultrasound-guided transbronchial biopsy.
Gefapixant 50 mg twice daily significantly reduced cough frequency in patients with refractory chronic cough and unexplained chronic cough after 12 weeks.
Merck announced topline data from 2 ongoing pivotal phase 3 trials (COUGH-1 and COUGH-2) for gefapixant (MK-7264) for the treatment of refractory or unexplained chronic cough.
In older women, the risk for major osteoporotic fracture is not associated with long-term inhaled corticosteroid use and consequent respiratory diseases.
We spoke with the founding director of the Center for Pulmonary Infection Research and Treatment, Charles Dela Cruz, MD, PhD, of Yale University to get a better understanding of the risks that COVID-19 may pose to patients with chronic lung disease.
A total of 7 differentially methylated CpG sites associated with mortality in people with ≥10 pack-years smoking history were identified in a genome-wide analysis.
During the period from 2010 to 2016, parents of children from low-income households were more likely to report recent childhood GI and respiratory illnesses than parents with a higher income.
Organizations including the CDC and FDA have been investigating the nationwide outbreak of e-cigarette or vaping product use–associated lung injury since August 2019.
